1. Determination of a New 5-Lipoxygenase Inhibitor, Zileuton, and its Inactive N-Dehydroxylated Metabolite in Plasma by High Performance Liquid Chromatography

   • G. Richard Granneman
   • Rene A. Braeckman
   • Keith A. Erdman

   OriginalPaper 25 October 2012 Pages: 1 - 8

2. The Pharmacokinetics of Single Oral Doses of Zileuton 200 to 800mg, its Enantiomers, and its Metabolites, in Normal Healthy Volunteers

   • Shekman L. Wong
   • Walid M. Awni
   • Louise M. Dubé

   OriginalPaper 25 October 2012 Pages: 9 - 21

3. Pharmacokinetics and Pharmacodynamics of Zileuton after Oral Administration of Single and Multiple Dose Regimens of Zileuton 600mg in Healthy Volunteers

   • Walid M. Awni
   • Rene A. Braeckman
   • Louise M. Dubé

   OriginalPaper 25 October 2012 Pages: 22 - 33

4. In Vitro Plasma Protein Binding of Zileuton and its N-Dehydroxylated Metabolite

   • Joseph M. Machinist
   • Michael J. Kukulka
   • Barbara A. Bopp

   OriginalPaper 25 October 2012 Pages: 34 - 41

5. The Pharmacokinetics of Zileuton in Healthy Young and Elderly Volunteers

   • Rene A. Braeckman
   • G. Richard Granneman
   • Walid M. Awni

   OriginalPaper 25 October 2012 Pages: 42 - 48

6. The Effect of Mild or Moderate Hepatic Impairment (Cirrhosis) on the Pharmacokinetics of Zileuton

   • Walid M. Awni
   • John H. Cavanaugh
   • G. Richard Granneman

   OriginalPaper 25 October 2012 Pages: 49 - 61

7. The Effect of Food on the Pharmacokinetics of Zileuton

   • Walid M. Awni
   • John H. Cavanaugh
   • Louise M. Dubé

   OriginalPaper 25 October 2012 Pages: 62 - 66

8. Pharmacodynamic and Stereoselective Pharmacokinetic Interactions between Zileuton and Warfarin in Humans

   • Walid M. Awni
   • Ziad Hussein
   • John H. Cavanaugh

   OriginalPaper 25 October 2012 Pages: 67 - 76

9. Effect of Zileuton on Theophylline Pharmacokinetics

   • G. Richard Granneman
   • Rene A. Braeckman
   • Walid M. Awni

   OriginalPaper 25 October 2012 Pages: 77 - 83

10. Lack of Pharmacokinetic Interaction between Zileuton and Phenytoin in Humans

    • Emil Samara
    • John H. Cavanaugh
    • G. Richard Granneman

    OriginalPaper 25 October 2012 Pages: 84 - 91

11. Assessment of the Pharmacokinetic Interaction between Zileuton and Digoxin in Humans

    • Walid M. Awni
    • Ziad Hussein
    • Louise M. Dubé

    OriginalPaper 25 October 2012 Pages: 92 - 97

12. The Influence of Multiple Oral Doses of Zileuton on the Steady-State Pharmacokinetics of Sulfasalazine and its Metabolites, Sulfapyridine and N-Acetylsulfapyridine

    • Walid M. Awni
    • Rene A. Braeckman
    • G. Richard Granneman

    OriginalPaper 25 October 2012 Pages: 98 - 104

13. Pharmacokinetic Interactions between Zileuton and Prednisone

    • Walid M. Awni
    • John H. Cavanaugh
    • Louise M. Dubé

    OriginalPaper 25 October 2012 Pages: 105 - 111

14. The Pharmacokinetic and Pharmacodynamic Interactions between the 5-Lipoxygenase Inhibitor Zileuton and the Cyclo-Oxygenase Inhibitor Naproxen in Human Volunteers

    • Walid M. Awni
    • Rene A. Braeckman
    • Louise M. Dubé

    OriginalPaper 25 October 2012 Pages: 112 - 124